FindTrial
Sign In

A clinical study to Evaluate the Effect of Fresh and Dry Amalaki Pindi (ocular poultice) in patients with Anterior Segment Inflammatory Eye Diseases-Acute Conjunctivitis ,Episcleritis and Dry Eye Syndrome.

Evaluation of Comparative Efficacy of Fresh and Dry Amalaki Pindi in the Management of Anterior Segment Inflammatory Eye Diseases-An Open Label Double Arm Exploratory Clinical Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/0100041
Enrollment
64
Registered
2026-01-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H049- Disorder of lacrimal system, unspecified Health Condition 2: H151- Episcleritis Health Condition 3: H102- Other acute conjunctivitis

Interventions

None listed

Sponsors

All India Institute Of Ayurveda , New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of Conjunctivitis or Dry eye with inflammation or Episcleritis with conjunctival hyperemia. 2. patients willing and able to participate in the study.

Exclusion criteria

Exclusion criteria: .Patients with other anterior segment eye diseases. 2.Patients with dry eye induced corneal denudation. 3. Patients with raised IOP more than 21 mm Hg in Non-contact tonometer or Schiotz tonometry. 4. Patients of severe dry eye syndrome with corneal and conjunctival staining. 5. Medically unfit for participating and completion of the trial. 6. Involvement in another interventional research study. 7. Patients suffering from systemic diseases such as hypertension , diabetes mellitus etc or chronic illnesses like HIV, Hepatitis B, or immunocompromise.

Design outcomes

Primary

MeasureTime frame
1.Reduction in conjunctival hyperemia as per Efron grading scale for bulbar conjunctival congestion, CCLRU scale of grading for palpebral conjunctival congestion. Timepoint: Assessment on day 0(baseline evaluation) , 3rd day,7th day and follow up on 14th day.—

Secondary

MeasureTime frame
1.Reduction in ocular pain in terms of VAS scale for ocular pain ,follicular grading of palpebral conjunctiva & chemosis for 7 days in patients of anterior segment inflammatory eye diseases. 2.Identification of key phytoconstituents from Amalaki pindi interacting with the targets of Anterior segment inflammatory eye diseases & predicting their binding affinity with Molecular Docking & Molecular Dynamics Simulations.Timepoint: Assessment on day 0(baseline evaluation) , 3rd day,7th day & follow up on 14th day.—

Countries

India

Contacts

Public ContactDr Bhanupriya R

All India Institute Of Ayurveda ,New Delhi

bhatrajma2008@gmail.com9560788850

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026